Johanna Waidhauser 1, Myriam Labopin 2,3, Jordi Esteve 4, Nicolaus Kröger 5, Jan Cornelissen 6, Tobias Gedde-Dahl 7, Gwendolyn Van Gorkom 8, Jürgen Finke 9, Montserrat Rovira 4, Nicolaas Schaap 10, Eefke Petersen 11, Dietrich Beelen 12, Donald Bunjes 13, Christoph Schmid 1, Arnon Nagler 14, Mohamad Mohty 2,3 1Universitiy Medical Center Augsburg, Augsburg, Germany, 2EBMT Paris Study Office, Hôpital Sain-Antoine, Paris, France, 3INSERM UMR 938, Sorbonne University, Paris, France, 4Hospital Clinic, Barcelona, Spain, 5University Hospital Eppendorf, Hamburg, Germany, 6Erasmus MC Cancer Institute, University Medical Center, Rotterdam, Netherlands, 7Oslo University Hospital, Oslo, Norway, 8University Hospital Maastricht, Maastricht, Netherlands, 9University of Freiburg, Freiburg, Germany, 10Nijmegen Medical Centre, Nijmegen, Netherlands, 11University Medical Center Utrecht, Utrecht, Netherlands, 12University Hospital Essen, Essen, Germany, 13Universitätsklinikum Ulm, Ulm, Germany, 14Chaim Sheba Medical Center, Tel Aviv University, Tel-Hashomer, Israelīackground: Acute myeloid leukemia with RUNX1 gene mutation (RUNX1+ AML) has been proposed as a provisional entity in the 2016 WHO classification.
0 kommentar(er)
